Research

Hormonal

SGLT2 inhibitors and GLP-1 receptor agonists provide cardiovascular benefits (reduced MACE and heart failure hospitalization) and slow kidney disease progression, distinct from older glucose-lowering drugs.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance, Farxiga) or GLP-1 agonists (like Ozempic, Trulicity). These drugs protect your heart and kidneys beyond just lowering sugar, unlike older diabetes medications.

StrongSupportsHIGH confidence
Some clinical trials with sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists reported data demonstrating cardiovascular benefit (decreased risk of major adverse cardiovascular events and hospitalization for heart failure) and slower progression of diabetic kidney disease.
Simeon I. Taylor et al. · Journal of Clinical Investigation · 2021

Why this rating

Based on multiple dedicated Cardiovascular Outcome Trials (CVOTs) and meta-analyses cited.

Source

Pharmacological treatment of hyperglycemia in type 2 diabetes

Simeon I. Taylor et al. · Journal of Clinical Investigation · 2021

DOI 10.1172/jci142243

narrative_reviewCited 243×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →